S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achaogen, Inc. stock logo
AKAOQ
Achaogen
$0.03
+0.8%
$0.02
$0.00
$0.05
$1.21M-0.81186,196 shs68,500 shs
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
$0.00
$0.00
$0.01
N/A1.13N/AN/A
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
$0.05
$0.05
$0.02
$0.25
$572K2.4713,394 shsN/A
Capstone Holding Corp. stock logo
CAPS
Capstone
$5.20
$5.20
$4.90
$20.00
N/A117.41N/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
$4.25
$2.46
$0.52
$9.12
$1.67M0.549,053 shsN/A
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achaogen, Inc. stock logo
AKAOQ
Achaogen
0.00%0.00%0.00%0.00%0.00%
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
0.00%0.00%0.00%0.00%0.00%
Capstone Holding Corp. stock logo
CAPS
Capstone
0.00%0.00%0.00%0.00%-85.95%
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
0.00%-10.34%+44.07%+90.58%-5.56%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/AN/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/AN/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/A
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/AN/A
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achaogen, Inc. stock logo
AKAOQ
Achaogen
$8.73M0.14N/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
$1.90M0.30N/AN/A($1.63) per share-0.03
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achaogen, Inc. stock logo
AKAOQ
Achaogen
-$186.51MN/A0.00N/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
-$40.57MN/A0.00N/AN/AN/AN/AN/A
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/A0.00N/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
-$160KN/A0.00N/AN/AN/A-159.55%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/A
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/AN/AN/A
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/A
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/AN/AN/A
Capstone Holding Corp. stock logo
CAPS
Capstone
N/AN/AN/A
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/A
0.15
0.15

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/A
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
N/A
Capstone Holding Corp. stock logo
CAPS
Capstone
2.55%
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Achaogen, Inc. stock logo
AKAOQ
Achaogen
7.80%
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
2.08%
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
28.21%
Capstone Holding Corp. stock logo
CAPS
Capstone
42.80%
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
18.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Achaogen, Inc. stock logo
AKAOQ
Achaogen
4248.21 millionN/ANot Optionable
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
21N/AN/ANot Optionable
Argos Therapeutics Inc stock logo
ARGSQ
Argos Therapeutics
2110.59 millionN/ANot Optionable
Capstone Holding Corp. stock logo
CAPS
Capstone
52N/AN/ANot Optionable
Peak Pharmaceuticals, Inc. stock logo
PKPH
Peak Pharmaceuticals
1392,000320,000Not Optionable

CAPS, PKPH, AKAOQ, ANTH, and ARGSQ Headlines

SourceHeadline
Kingswood Capital Management Acquires PATCO ProductsKingswood Capital Management Acquires PATCO Products
preparedfoods.com - April 8 at 2:39 PM
Akari Therapeutics Signs Merger-of-Equals with Peak BioAkari Therapeutics Signs Merger-of-Equals with Peak Bio
marketwatch.com - March 5 at 10:22 AM
Akari Therapeutics, Peak Bio Announces Agreement To Merge As Equals - Quick FactsAkari Therapeutics, Peak Bio Announces Agreement To Merge As Equals - Quick Facts
markets.businessinsider.com - March 5 at 10:22 AM
Vote NowVote Now
cbc.ca - February 19 at 5:55 PM
Buy Rating Affirmed for Longboard Pharmaceuticals Amid Strong Bexicaserin Phase 2 Results and Blockbuster Revenue PotentialBuy Rating Affirmed for Longboard Pharmaceuticals Amid Strong Bexicaserin Phase 2 Results and Blockbuster Revenue Potential
markets.businessinsider.com - January 9 at 8:51 AM
Shares of Mankind Pharma Fall as Stakeholders Consider Reducing HoldingsShares of Mankind Pharma Fall as Stakeholders Consider Reducing Holdings
claytoncountyregister.com - December 12 at 8:40 AM
Hallowed Peak: Lunar FestivalHallowed Peak: Lunar Festival
timeout.com - October 31 at 10:25 PM
Peak Practice is axedPeak Practice is axed
dailymail.co.uk - June 14 at 10:21 AM
Is Peak Pharmaceuticals Inc (RMHI) Stock a Good Investment?Is Peak Pharmaceuticals Inc (RMHI) Stock a Good Investment?
aaii.com - June 6 at 12:41 PM
Peak Pharmaceuticals & Retrieve Medical Announce Signed Contract with Regional Medical CenterPeak Pharmaceuticals & Retrieve Medical Announce Signed Contract with Regional Medical Center
benzinga.com - May 31 at 2:41 PM
Peak Pharmaceuticals & Retrieve Medical Announce Signed Contract with Regional Medical CenterPeak Pharmaceuticals & Retrieve Medical Announce Signed Contract with Regional Medical Center
finance.yahoo.com - May 31 at 2:41 PM
Minnesota patients and providers navigate ‘historical peak’ of drug shortagesMinnesota patients and providers navigate ‘historical peak’ of drug shortages
mprnews.org - May 5 at 10:10 PM
Peak to Peak Charter SchoolPeak to Peak Charter School
usnews.com - May 2 at 10:12 AM
Peak Pharmaceuticals Merges with Retrieve Medical, Inc.Peak Pharmaceuticals Merges with Retrieve Medical, Inc.
finance.yahoo.com - March 28 at 1:28 PM
PKPHD Peak Pharmaceuticals, Inc.PKPHD Peak Pharmaceuticals, Inc.
seekingalpha.com - February 23 at 10:15 PM
Peak Pharmaceuticals Announces One-for-Two-Hundred Reverse Stock SplitPeak Pharmaceuticals Announces One-for-Two-Hundred Reverse Stock Split
finance.yahoo.com - February 14 at 6:03 PM
Peak Pharmaceuticals, Inc.: Peak Pharmaceuticals Announces One-for-Two-Hundred Reverse Stock SplitPeak Pharmaceuticals, Inc.: Peak Pharmaceuticals Announces One-for-Two-Hundred Reverse Stock Split
finanznachrichten.de - February 14 at 1:03 PM
Mirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo PharmaMirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo Pharma
seekingalpha.com - February 1 at 8:04 AM
BMO says this stock taking gene therapy to the next level can more than doubleBMO says this stock taking gene therapy to the 'next level' can more than double
cnbc.com - January 30 at 10:24 AM
Peak to Peak Mountain Charter School sees 2-hour delayPeak to Peak Mountain Charter School sees 2-hour delay
turnto23.com - January 12 at 7:50 PM
Should You Buy Biogen Stock After Its Latest Alzheimers Disease Drug Approval?Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
msn.com - January 10 at 8:56 AM
Is Peak Pharmaceuticals Inc (PKPH) Stock a Good Investment?Is Peak Pharmaceuticals Inc (PKPH) Stock a Good Investment?
aaii.com - January 2 at 2:13 PM
Horizon Therapeutics fields buyout interest from Amgen, J&J and SanofiHorizon Therapeutics fields buyout interest from Amgen, J&J and Sanofi
cnbc.com - November 29 at 7:52 PM
PKPH Peak Pharmaceuticals, Inc.PKPH Peak Pharmaceuticals, Inc.
seekingalpha.com - October 15 at 8:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Achaogen logo

Achaogen

OTCMKTS:AKAOQ
Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.
Anthera Pharmaceuticals logo

Anthera Pharmaceuticals

OTCMKTS:ANTH
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
Argos Therapeutics logo

Argos Therapeutics

OTCMKTS:ARGSQ
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. On November 30, 2018, Argos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware.
Capstone logo

Capstone

OTCMKTS:CAPS
Capstone Holding Corp., through its subsidiaries, engages in the distribution of masonry stone products in the United States. Its masonry stone products include manufactured and natural stone veneer sidings, hardscapes and related moisture management products, lath products, and fireplaces offered under the Instone and Northeast Masonry names for residential and commercial construction. The company was formerly known as Capstone Therapeutics Corp. and changed its name to Capstone Holding Corp. in February 2022. Capstone Holding Corp. was incorporated in 1987 and is headquartered in Tempe, Arizona. Capstone Holding Corp. operates as a subsidiary of BP Peptides, LLC
Peak Pharmaceuticals logo

Peak Pharmaceuticals

OTCMKTS:PKPH
Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ.